Evaluation of five DNA extraction methods for purification of DNA from atherosclerotic tissue and estimation of prevalence of Chlamydia pneumoniae in tissue from a Danish population undergoing vascular repair by Mygind, Tina et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Microbiology
Open Access Research article
Evaluation of five DNA extraction methods for purification of DNA 
from atherosclerotic tissue and estimation of prevalence of 
Chlamydia pneumoniae in tissue from a Danish population 
undergoing vascular repair
Tina Mygind*1, Lars Østergaard2, Svend Birkelund1, Jes S Lindholt3 and 
Gunna Christiansen1
Address: 1Department of Medical Microbiology and Immunology, Wilhelm Meyers Allé, The Bartholin Building, University of Aarhus, DK-8000 
Aarhus C, Denmark, 2Research Unit Q, Department of Infectious Diseases, Skejby Hospital, University Hospital of Aarhus, Brendstrupgaardsvej, 
DK-8200 Aarhus N, Denmark and 3Department of Vascular Surgery, Viborg Hospital, Viborg, Denmark
Email: Tina Mygind* - mygind@biobase.dk; Lars Østergaard - oes@sks.aaa.dk; Svend Birkelund - chlam@medmicro.au.dk; 
Jes S Lindholt - jslindholt@mail.tele.dk; Gunna Christiansen - gunna@medmicro.au.dk
* Corresponding author    
Chlamydia pneumoniaeatherosclerotic tissueDNA extractionreal-time PCR
Abstract
Background: To date PCR detection of Chlamydia pneumoniae DNA in atherosclerotic lesions
from Danish patients has been unsuccessful. To establish whether non-detection was caused by a
suboptimal DNA extraction method, we tested five different DNA extraction methods for
purification of DNA from atherosclerotic tissue.
Results:  The five different DNA extraction methods were tested on homogenate of
atherosclerotic tissue spiked with C. pneumoniae DNA or EB, on pure C. pneumoniae DNA samples
and on whole C. pneumoniae EB. Recovery of DNA was measured with a C. pneumoniae-specific
quantitative real-time PCR. A DNA extraction method based on DNA-binding to spin columns
with a silica-gel membrane (DNeasy Tissue kit) showed the highest recovery rate for the tissue
samples and pure DNA samples. However, an automated extraction method based on magnetic
glass particles (MagNA Pure) performed best on intact EB and atherosclerotic tissue spiked with
EB. The DNeasy Tissue kit and MagNA Pure methods and the highly sensitive real-time PCR were
subsequently used on 78 atherosclerotic tissue samples from Danish patients undergoing vascular
repair. None of the samples were positive for C. pneumoniae DNA. The atherosclerotic samples
were tested for inhibition by spiking with two different, known amounts of C. pneumoniae DNA and
no samples showed inhibition.
Conclusion: As a highly sensitive PCR method and an optimised DNA extraction method were
used, non-detection in atherosclerotic tissue from the Danish population was probably not caused
by use of inappropriate methods. However, more samples may need to be analysed per patient to
be completely certain on this. Possible methodological and epidemiological reasons for non-
detection of C. pneumoniae DNA in atherosclerotic tissue from the Danish population are
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discussed. Further testing of DNA extraction methods is needed as this study has shown
considerable intra- and inter-method variation in DNA recovery.
Background
Chlamydia pneumoniae is an important cause of human
respiratory tract diseases [1]. The organism has also been
associated with atherosclerosis and thromboembolic
events by use of seroepidemiology and direct detection of
the organism in atherosclerotic plaques [2]. Although the
presence of C. pneumoniae DNA has been observed in
atherosclerotic lesions, the pathological or clinical signif-
icance is unknown and difficult to elucidate. One of the
keys to answering these questions could be identifying
differences between populations in which the organism is
detected and populations in which it is not. In contrast to
populations outside Denmark [3–5] attempts to detect C.
pneumoniae in atherosclerotic tissue obtained from Danes
have not been successful [6,7].
The issue of methodology is highly relevant when consid-
ering whether or not Danes are infected by C. pneumoniae
in vascular tissue. A recent study [8] showed major inter-
laboratory variation between C. pneumoniae PCR and
DNA extraction methods even when they were applied on
the same set of samples. A reasonable assumption could
therefore be that former Danish studies with negative
findings used PCR tests that were too insensitive to allow
detection or that DNA extraction methods were insuffi-
cient to remove inhibitors.
In order to confirm and justify the previous Danish find-
ings we conducted a study to find the DNA preparation
method with the highest obtainable DNA recovery and
inhibitor removal. We examined five different methods
for purifying DNA from atherosclerotic tissue. The recov-
ery of DNA from three different sample types was tested
with a quantitative real-time PCR specific for C. pneumo-
niae  [9,10]. The best DNA purification method was
selected and used in combination with the C. pneumoniae-
specific real-time quantitative PCR to assess the preva-
lence of C. pneumoniae DNA in atherosclerotic tissue sam-
ples from patients undergoing vascular repair. Inhibition
in the samples was tested by spiking aliquots of the
atherosclerotic tissue DNA samples with a known amount
of C. pneumoniae DNA before subjecting them to PCR.
Results
By a literature search we selected the five most commonly
used DNA extraction methods; 1) a standard phenol/chlo-
roform purification method followed by an ethanol pre-
cipitation, 2) same method as 1) but with a
cetyltrimethylammonium bromide (CTAB) precipitation
step included (at high NaCl CTAB precipitates polysaccha-
rides and proteins) [11], 3) the DNeasy Tissue kit from
Qiagen, a silica-gel column-based method, 4) the Easy-
DNA kit from Invitrogen [12] 5) and the MagNA Pure LC
Instrument that provides automated DNA purification
based on magnetic glass particles. DNA purification meth-
ods were tested on the following sample panels 1) sam-
ples with purified C. pneumoniae genomic DNA in
concentrations of 105,103, 10 copies/µl and a negative
control, 2) spiked aorta homogenate samples (10 mg tis-
sue pr. sample) with C. pneumoniae genomic DNA concen-
trations of 105, 103, 10 copies/µl and a negative control.
3) Purified, intact C. pneumoniae EB in dilutions 1.2 × 10-
4, 1.2 × 10-5, 1.2 × 10-6, 1.2 × 10-8 and a negative control
containing PBS only (corresponding to approximate EB
concentrations of 2000, 200, 20, 0.2 and 0 EB/µl). 4)
Aorta homogenate samples spiked with intact C. pneumo-
niae EB in dilutions 1.2 × 10-4, 1.2 × 10-5, 1.2 × 10-6, 1.2 ×
10-8 and a negative control (corresponding to approxi-
mate EB concentrations of 2000, 200, 20, 0.2 and 0 EB/
µl). See the methods section for a detailed description of
the samples. Purified C. pneumoniae genomic DNA was
used for spiking of sample panel 1 because the exact
amount of DNA input is known as opposed to the C. pneu-
moniae EB, which are difficult to quantify. Consequently,
copies/µl refer to genome copy number. EB were also used
alone and for spiking of aorta homogenate to test the
methods for their capability of recovering DNA from
intact bacteria. To simplify determination of how much
DNA was recovered the input and output volume (100 µl)
for the DNA extraction was the same for each sample.
After DNA extraction the amount of recovered DNA was
measured with a C. pneumoniae-specific real-time quanti-
tative PCR on 2 µl of the output volume. Table 1 shows
input copies/µl, mean output copies/µl for two replicates,
and the recovery percentage for the pure C. pneumoniae
genomic DNA samples and aorta samples spiked with C.
pneumoniae genomic DNA. Table 2 shows input EB dilu-
tion/ concentration, mean output copies/µl for two repli-
cates, and the relative recovery percentage for pure C.
pneumoniae EB samples and aorta samples spiked with C.
pneumoniae EB.
Pure DNA samples
All negative samples were correctly identified as negative,
meaning that no contamination was introduced during
purification. Four methods (phenol/chloroform, The
DNeasy Tissue kit, Easy-DNA kit, MagNA Pure) were able
to recover C. pneumoniae DNA from the lowest concentra-
tion sample (input concentration 10 copies/µl) with out-
put concentrations ranging from 0.6–8 copies/µl (TableBMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/19
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1). For an input of 103 copies/µl output concentrations
ranged from 12–658 copies/µl and for an input of 105
copies/µl output concentrations ranged from 728–7.5 ×
104 copies/µl (Table 1). For all input DNA concentrations
the DNeasy Tissue kit showed the highest output concen-
tration. Consequently, for the pure C. pneumoniae DNA
samples the DNeasy Tissue kit had the best average recov-
ery percentage (74.0%) followed by the MagNA pure with
an average recovery percentage of 50.9%. All five methods
showed approximately 10% intra-method difference
between the highest and lowest recovery percentages.
Homogenised aorta tissue spiked with DNA
All negative samples were correctly identified. Four meth-
ods (phenol/ chloroform + CTAB, The DNeasy Tissue kit,
Easy-DNA kit, MagNA Pure) recovered C. pneumoniae
DNA from the lowest input concentration sample (10
copies/µl) with output concentrations ranging from 1.3–
6.3 copies/µl (Table 1) and the Easy-DNA kit had the
highest output concentration. For an input of 103 copies/
µl output concentrations ranged from 13–285 copies/µl
and the DNeasy Tissue kit had the highest output concen-
tration. For an input of 105 copies/µl output concentra-
tions ranged from 1.4 × 103-3.3 × 104 copies/µl and the
Easy-DNA kit had the highest output concentration. The
range of recovery percentages obtained with one method
was larger than for the pure DNA samples. For the spiked
aorta samples the Easy-DNA kit had the best recovery per-
centage (40.6%) and the DNeasy Tissue kit the second
best (32.6%).
Purified EB samples
All negative samples were correctly identified. No meth-
ods recovered C. pneumoniae DNA from the lowest EB
dilution 1.2 × 10-8 (~0.2 EB/µl), but all methods recovered
C. pneumoniae DNA from 1.2 × 10-6, 1.2 × 10-5 and 1.2 ×
10-4 dilutions (~2000, 200, 20 EB/µl) (Table 2). Recovery
percentages were calculated relatively to the method per-
forming best. The MagNA Pure method performed best
and showed the highest output concentrations for all dilu-
tions. The DNeasy Tissue kit showed relative recovery per-
centages from 79.8–95.3%. The Easy-DNA kit showed the
lowest relative recovery percentages from 1.5–5.3%. The
phenol/chloroform+CTAB method showed the second
lowest recovery percentages (11.4–35.8%) and the phe-
nol/chloroform the third lowest recovery percentages
(20.2–42.8%) (Table 2).
Homogenised aorta tissue spiked with purified EB
All negative samples were correctly identified. Two meth-
ods recovered C. pneumoniae DNA from the lowest dilu-
tion 1.2 × 10-8 (~0.2 EB/µl); phenol/chloroform + CTAB
Table 1: Five DNA extraction methods used on pure C. pneumoniae DNA and aorta tissue samples spiked with C. pneumoniae DNA For 
each sample type different DNA input concentrations were used, these are displayed in the first column. DNA input concentration was 
known as pure genomic C. pneumoniae DNA was used for preparation of samples. For each method and sample the mean output C. 
pneumoniae genomic DNA concentration and standard deviation (SD) is displayed for two replicates as determined with the 
quantitative pmp4 LightCycler PCR. In addition percentage of recovered DNA is calculated (% Rec.). Standard deviations (SD) are also 
shown for the recovery percentages.
phenol/chloroform phenol/chloroform +CTAB DNeasy Tissue kit Easy-DNA kit Magna Pure
Input 
copies 
/µl
Mean 
output 
copies/
µl
SD of 
Mean
%
Rec.
SD 
of % 
Rec.
Mean 
output 
copies/
µl
SD of 
Mean
% 
Rec.
SD of 
% 
Rec.
Mean 
output 
copies/
µl
SD of 
Mean
% 
Rec.
SD 
of % 
Rec.
Mean 
output 
copies/
µl
SD of 
Mean
% 
Rec.
SD of 
% Rec.
Mean 
output 
copies/
µl
SD of 
Mean
% 
Rec.
SD of 
% Rec.
Pure C. 
pneumoniae 
DNA sam-
ples
0 0 0- -0 0- -0 0-- 0 0-- 0 0- -
10 1.79 0.213 17.9 2.1 0 0 0.0 0 8.08 1.21 80.8 12.1 0.661 0.520 6.6 5.2 4.60 0.377 46.0 3.8
103 296 15.4 29.6 1.5 11.8 3.20 1.2 0.3 658 77.7 65.8 7.8 48.9 14.5 4.9 1.4 508 49.0 50.8 4.9
105 2.09 × 
104
2.55 × 
103
20.9 2.5 728 107 0.7 0.1 7.54 × 
104
1.83 × 
104
75.4 18.4 3.10 × 
103
1.83 × 
103
3.1 1.8 5.58 × 
104
7.54 
× 103
55.8 7.5
av rec 
%
- - 22.8 5.7 -- 0 . 6 0.6 -- 7 4 . 0 12.4 -- 4 . 9 3.0 - - 50.9 6.2
Aorta tis-
sue samples 
spiked with 
C. pneumo-
niae DNA
0 0 0- -0 0- -0 0-- 0 0-- 0 0- . -
10 0 0 0.0 0 1.31 0.240 13.1 2.4 4.56 4.19 45.6 42.0 6.34 1.50 63.4 15.0 1.83 0.622 18.3 6.2
103 70.8 32.7 7.1 3.3 13.0 6.46 1.3 0.6 285 23.9 28.5 2.4 255 13.7 25.5 1.4 82.0 6.08 8.2 0.6
105 5.00 × 
103
2.55 × 
103
5.0 2.4 1.40 × 
103
611 1.4 1.0 2.37 × 
104
502 23.7 0.5 3.30 × 
104
7.53 × 
103
33.0 7.5 1.61 × 
104
1.06 
× 104
16.1 10.6
av rec 
%
-- 4 . 0 3.7 -- 5 . 3 6.2 -- 3 2 . 6 21.4 - - 40.6 19.4 - - 14.2 7.3
over-
all 
avrec 
%
- - 13.4 10.8 -- 3 . 0 4.8 -- 5 3 . 3 27.3 - - 22.8 22.9 - - 32.5 20.2BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/19
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and the MagNA Pure method (Table 2). From all other
dilutions (~2000, 200, 20 EB/µl) (except one; 1.2 × 10–-5,
where the phenol/chloro-form+CTAB method showed
higher recovery) the MagNA Pure method also showed
highest output DNA concentrations and thereby the best
performance. The phenol/chloroform+CTAB method
showed from 18.0–110.5% relative recovery and the
DNeasy Tissue kit showed between 58.7–73.7% relative
recovery. The phenol/chloroform (44.5–53.2%) and
Easy-DNA kit methods (12.3–26.1%) showed the lowest
relative recovery percentages (Table 2). For the two best
methods (MagNA Pure and DNeasy) the whole process
from DNA extraction to PCR detection had a sensitivity of
less than approximately 20 EB/µl (concentration in sam-
ples before DNA extraction) (Table 2).
Combined test results
When comparing recovery percentages for the pure DNA
samples and the aorta samples spiked with DNA, it is seen
that there was greater intra-method variation for the
spiked aorta samples. For two methods (phenol/chloro-
form+CTAB and Easy-DNA kit) the recovery percentage
was generally lower for the pure DNA samples (Table 1).
When the overall recovery percentage was calculated for
all samples for each method, the DNeasy Tissue kit had
the best recovery percentage (53.3%) and MagNA Pure the
second best (32.5%) (Table 1). On the pure EB samples
and aorta samples spiked with EB, the MagNA Pure
method performed best and the DNeasy Tissue kit second
best (Table 2). For two methods the phenol/ chloro-
form+CTAB and Easy-DNA kit performance was best on
aorta samples spiked with EB analogous to the situation
on aorta samples spiked with pure DNA. On the basis of
these combined results the DNeasy Tissue kit and the
MagNA Pure methods were chosen for tests on patient
samples.
Patient samples
The DNeasy Tissue kit and the MagNA Pure method were
tested for purification of DNA from 78 atherosclerotic
samples. None of the 2 × 78 DNA preparations were pos-
itive for C. pneumoniae and all samples were positive for
human DNA. The average human DNA concentration in
the samples purified with the DNeasy Tissue kit was 1.1 ×
104 copies/µl (SD = 1.6 × 104, range 6.2 × 102 to 1.1 × 105
copies/µl). The average human DNA concentration in
samples purified with the MagNA Pure was 1.0 × 104 cop-
ies/µl (SD = 1.1 × 104 copies/µl, range 18 to 5.4 × 104 cop-
ies/µl). As an inhibition check all samples purified with
both methods were spiked with two different, known con-
centrations of C. pneumoniae genomic DNA (103 copies/µl
and 10 copies/µl). Subsequently, the spiked samples were
subjected to real-time quantitative PCR. Here we found
that both concentrations could be detected in all 78 sam-
ples using both extraction methods. The average C. pneu-
moniae concentration in the 78 samples purified with the
DNeasy tissue kit and spiked with 10 copies/µl were 14.2
copies/µl (SD = 5.4) and in samples spiked with 103 cop-
Table 2: Five DNA extraction methods used: pure intact C. pneumoniae EB and aorta tissue samples spiked with C. pneumoniae EB For 
each sample type different EB input dilutions were used, these are displayed in the first column. Shown are also a rough estimate of the 
EB concentrations as determined by real-time PCR. For each method and sample the mean output C. pneumoniae genomic DNA 
concentration and standard deviation (SD) is displayed for two replicates as determined with the quantitative pmp4 LightCycler PCR. 
In addition relative recovery percent is calculated relative to the best method, which in this case was the MagNA Pure method (% Rel. 
rec.). Additionally standard deviations (SD) are also shown for the relative recovery percentages.
phenol/chloroform phenol/chloroform + CTAB DNeasy Tissue kit Easy-DNA kit Magna Pure
EB 
Dilution
Appr. 
EB 
conc. 
EB/µl
Mean 
output 
copies/
µl
SD of 
Mean
% 
Rel. 
rec.
SD of % 
Relative 
rec.
Mean 
output 
copies/
µl
SD of 
Mean
% 
Rel. 
rec.
SD of % 
Relative 
rec.
Mean 
output 
copies/
µl
SD of 
Mean
% 
Rel. 
rec.
SD of % 
Relative 
rec.
Mean 
output 
copies/
µl
SD of 
Mean
% 
Rel. 
rec.
SD of % 
Relative 
V
Mean 
output 
copies/
µl
SD of 
Mean
% 
Rel. 
rec.
SD of % 
Relative 
rec.
C. 
pneumon
iae EB 
samples
n e g a t i v e 0 0 0 - -0 0 - -0 0 - -0 0 - -0 0 - -
1.2 × 10-8 0 . 2 0 0 - -0 0 - -0 0 - -0 0 - -0 0 - -
1.2 × 10-6 20 3.76 4.60 42.8 52.4 1.38 0.410 15.8 4.7 8.36 3.59 95.3 40.9 0.464 0.160 5.3 1.8 8.78 0.005 100 0.06
1.2 × 10-5 200 28.6 29.9 27.0 28.2 38.0 44.7 35.8 42.2 96.2 19.3 90.8 18.2 1.81 1.24 1.7 1.2 106 38.3 100 36.2
1.2 × 10-4 2000 248 208 20.2 17.0 140 60.2 11.4 5.0 982 250 79.8 20.3 18.5 21.7 1.5 1.8 1.23 × 
103
331 100 26.9
av rec % - - - 30.0 29.5 - - 21.0 22.3 - - 88.6 23.1 -- 2 . 8 2.3 - - 100 20.2
EB 
spiked 
aorta 
tissue 
samples
n e g a t i v e 0 0 0 - -0 0 - -0 0 - -0 0 - -0 0 - -
1.2 × 10-8 0.2 0 0 0 0 0.219 0.310 18.0 25.4 0 0 0 0 0 0 0 0 1.22 1.72 100 141.3
1.2 × 10-6 20 10.1 3.92 53.2 20.7 14.3 7.05 75.6 37.3 13.9 4.82 73.7 25.5 2.33 0.184 12.3 1.0 18.9 2.86 100 15.1
1.2 × 10-5 200 50.3 24.4 44.5 21.6 125 7.14 110.5 6.3 66.3 30.2 58.7 26.8 29.5 1.11 26.1 1.0 113 0.530 100 0.5
1.2 × 10-4 2000 632 177 49.0 13.7 648 585 50.3 45.3 869 208 67.3 16.2 191 128 14.8 9.9 1.29 × 
103
247 100 19.2
av rec % - - - 36.7 26.0 - - 63.6 43.7 - - 49.9 34.8 - - 13.3 10.6 - - 100 54.2
overall 
av rec %
-- -3 3 . 8 26.7 - - 45.3 41.2 66.5 35.4 8.8 9.6 100 41.7BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/19
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ies /µl it was 1.1 × 103 copies/µl (SD = 185). The average
C. pneumoniae concentration in the 78 samples purified
with the MagNA Pure method and spiked with 10 copies/
µl were 17.9 copies/µl (SD = 9.5) and in samples spiked
with 103 copies /µl it was 1.4 × 103 copies/µl (SD = 287).
Discussion
DNA purification methods
Two methods (phenol/chloroform+CTAB and Easy-DNA
kit) performed better on the spiked homogenates than on
pure C. pneumoniae DNA or EB (Table 1 and 2). It could
reflect that in general these two purification methods per-
form better on the tissue samples as the purification kinet-
ics is probably different in the two sample types. The Easy-
DNA kit was used strictly as recommended by the manu-
facturers and not with the improvements done by Meijer
et al. [12]. They replaced the ethanol precipitation by fur-
ther purification with silica particles and it was scaled up
to enable DNA purification from 300 mg of tissue. This
gave better sensitivity [12], so if we used their modifica-
tion, the Easy-DNA kit might have performed better. Loss
of DNA could be caused by precipitation, phenol/chloro-
form or chloroform extraction steps, as these steps are
prone to DNA loss. This is also indicated by the fact that
Meijer et al. [12] could improve the Easy-DNA method by
replacing the precipitation step with silica-particles. The
phenol/chloroform+CTAB method contains an addi-
tional precipitation step (CTAB) compared to conven-
tional phenol/chloroform extraction, which may account
for its relatively poor performance with pure DNA. The
three remaining methods (phenol/chloroform, DNeasy
Tissue kit and MagNA Pure) all showed reduced recovery
for the homogenates. The DNeasy Tissue kit showed the
best recovery on both pure DNA samples and aorta
homogenates spiked with DNA. On purified EB and aorta
homogenate spiked with EB the MagNA Pure method per-
formed best. That two different methods were found to be
best, probably reflects the different nature of the samples
and underlines the importance of using whole bacteria
and not just pure DNA for testing of extraction methods.
The two best methods (The DNeasy Tissue kit and the
MagNA Pure method) were chosen for use on patient
samples. These methods possibly perform better because
they contain few steps and because they do not contain
any precipitation steps. A recent study comparing DNA
extraction methods for extraction of C. pneumoniae DNA
from vascular tissue also found a spin-column method
(QIAamp DNA MiniKit) to give the best recovery [13].
Another study tested recovery percentages of five different
spin-column DNA extraction methods for purification of
viral DNA from serum samples. Here recovery percentages
were also determined with quantitative PCR in the Light-
Cycler and the QIAamp Blood kit (uses same principle as
DNeasy and is manufactured by Qiagen) showed a rela-
tive recovery percentage of 76% [14] comparable to our
absolute overall recovery percentage of 53.3%. and overall
average relative recovery of 66.5%.
From Tables 1 and 2 it is apparent that there is considera-
ble variation in how much DNA could be recovered even
within methods (3.0–53.3% overall average recovery and
8.8–100% overall average relative recovery). Real-time
quantitative PCR uses a point (the threshold cycle or
crossing point) at the beginning of the log-phase of the
PCR to determine the original target DNA concentration.
This gives a more realistic, though not perfect picture, of
the actual DNA concentration in the sample tested. The
variation would not have been as apparent if PCR prod-
ucts had been analysed by gel electrophoresis [12,15] or
time-resolved fluorometry (TRF) [6]. When comparing
PCR bands in a gel or PCR product amounts by TRF they
represent the end points of the PCRs (i.e. at the plateau
phase of the PCR) and they are often very similar even for
very different initial target DNA concentrations, especially
if many PCR cycles are performed. Therefore, previous
studies have probably not been fully aware of the actual
variation in output of DNA from their extraction methods
and therefore our results may seem highly variable in
comparison. In the study comparing different spin-col-
umn methods for DNA purification, they found relative
recovery percentages between 2.2–76% [14]. Therefore, it
is apparent that even among methods based on similar
principles there can be large differences in recovery of
DNA [14].
Another reason for the apparent variability could be that
the number determined by the real-time PCR depends not
only on how much DNA is actually present, but also on
the amount of inhibitors left in the sample, which will
add further variation. It could be speculated that methods
with low recovery percentages do not remove inhibitors
sufficiently and are prone to DNA loss during purifica-
tion, which in combination may give rise to the low recov-
ery as measured by real-time PCR. In the early days of real-
time PCR an estimation of the inhibition in the sample
was obtained by calculating PCR efficiency for each sam-
ple using a dilution curve [16]. This was based on the
assumption (and also other assumptions not mentioned
here) that PCR efficiency is constant during the entire run,
which stems from the PCR kinetics model currently used
in the LightCycler software Rn = R0 *(1+E)n (Rn: Fluores-
cence at cycle number n, R0: initial amount of target, E:
PCR efficiency). However, recent publications have indi-
cated that this may not reflect the real PCR kinetics in a
given sample as the efficiency varies form cycle to cycle
and because other parameters in a sigmoidal model are
probably better suited to describe the kinetics [17,18]. As
it is still unclear how PCR kinetics is best described and
how much trivial factors like variation in reaction compo-
nents, thermal cycling conditions and mispriming eventsBMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/19
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contribute to deviations in PCR kinetics we have not
incorporated PCR kinetics in the interpretation of our
data. However, investigation of PCR kinetics under differ-
ent conditions would clearly be helpful in selecting DNA
extraction methods suitable for samples to be used in real-
time PCR, as it possibly could be used to estimate the level
of inhibition in the samples. This should obviously be a
subject for future studies.
The rationale for using purified C. pneumoniae DNA in
some of the samples was that input and output DNA con-
centrations were known or could be determined. How-
ever, this does not test whether the DNA extraction
methods are capable of recovering DNA from whole EB.
Therefore a test using tissue spiked with purified EB was
also performed. It should be noted that this will not
entirely reflect reality either as normally the EB are present
inside human cells. Interestingly, the DNeasy Tissue kit
has been used on lungs from mice experimentally infected
with C. pneumoniae and here the kit was able to recover C.
pneumoniae  DNA amplifiable by real-time PCR [10].
Therefore, this kit is actually able to recover C. pneumoniae
DNA from a real infection where the bacteria are present
inside cells. Our study in combination with the study by
Apfalter et al. [8] indicate that more work is needed to
optimise DNA extraction methods. Automated DNA
extraction methods like the MagNA Pure method used in
this study may be the future choice, as these methods may
be able to produce more reproducible results, but this
remains to be examined more carefully.
Patient samples
The DNeasy Tissue kit and the MagNA Pure method were
used on 78 atherosclerotic tissue samples and subse-
quently amounts of C. pneumoniae DNA and human DNA
were determined with quantitative real-time PCR. We
found no samples positive for C. pneumoniae DNA. All
samples were positive for human DNA. As there was great
variation in the amount of human DNA among samples,
it could be suspected that low human DNA numbers are
caused by inhibitors, as the tissue input in mg should be
approximately equal for the samples. However, athero-
sclerotic tissue shows a very complex and variable compo-
sition which may contribute to the variability observed.
Some tissue samples may contain high levels of calcium,
which will decrease the amount of human DNA, or a high
number of inflammatory cells, which will increase the
amount of human DNA. The high variability in human
DNA recovery from the patient samples can lead to the
speculation that there may also be a high variability in
recovery of C. pneumoniae DNA, especially as the bacte-
rium is obligate intracellular. Therefore, as it has been pro-
posed by a recent Australian study [19], it may be
necessary to analyse more samples (up to 15 samples
according to [19]) from different artery locations in each
patient in order to obtain the true number of C. pneumo-
niae positive patients. This is according to this study [19]
advantagous because the distribution of C. pneumoniae
over the tissue is patchy and bacteria are present in low
numbers. It should be noted though that using single ran-
dom sections from 10 patients the Australian study found
from 35.6–41.6% percent positives [19], whereas we find
no positives in 78 patients using two samples purified
with two different DNA extraction methods from the
same site. Therefore, we will probably not observe as high
numbers of positive patients even though more samples
per patient were analysed. Especially in this experimental
context where the PCR sensitivity is 2 genomes in the puri-
fied sample amount loaded directly into the PCR tube [9]
and the sensitivity of the whole process of DNA extraction
followed by PCR is less than 20 EB/µl (concentration in
samples before DNA extraction).
It is highly probable that there are larger amounts of
human DNA than of C. pneumoniae DNA present in the
samples. Accordingly, inhibition will have a greater effect
on the C. pneumoniae PCR results and consequently the
human DNA PCR cannot be used as an inhibition control.
Therefore, inhibition was tested in the samples by spiking
them with two concentrations of C. pneumoniae DNA
before PCR. Hereby, we found that the C. pneumoniae
DNA could be detected in all samples. Therefore, it seems
that the DNeasy Tissue kit and the MagNA Pure method
did remove inhibitors sufficiently.
Short review of previously published studies on detection 
of C. pneumoniae in atherosclerotic tissue
To study whether there were methodological differences
between studies with positive and negative results we
compared all the negative studies with a selection of rep-
resentative positive studies (Table 3). The positive studies
were selected so that they represented studies both with
high and low prevalence of C. pneumoniae and the entire
span of years of C. pneumoniae direct detection in tissue
by PCR. Furthermore, different countries were repre-
sented. Among the positive studies The QIAamp Tissue Kit
and variations of phenol/chloroform extractions were
mostly used. Most of the positive studies declare that they
attempt to control contamination at some level, at least
with reagent negative controls in the PCR runs. The early
negative studies [25–27] only used Proteinase K as DNA
extraction method, which may not be sufficient as, in
most cases, it will leave behind many potential inhibitors.
However, one of the positive studies did use Proteinase K
only for extraction [32]. The Chelex [100 method used in
one of the negative studies [7] may not be sufficient for
purification either as it only removes multivalent cat ions
and lyse cells [41]. The rest of the negative studies used
DNA extraction methods optimised by their own labora-
tory [15] or methods also used by positive studies [6,20–BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/19
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22]. Two negative studies used the modified version of the
Easy-DNA kit [23,24]. This means that at least 7/11 nega-
tive studies used a DNA extraction method that should be
suitable for purification of DNA from tissue. Four of these
studies did also check sufficiently for PCR inhibition
[6,21,22,24], but it is unclear whether the three other
studies did [23,15,20]. Not surprisingly, some of the neg-
ative studies did use a DNA extraction method which
might have been insufficient (4/11 negative studies).
Three of these studies did check for inhibitors, by either
addition of an internal processing control to the samples
[7], spiking samples with C. pneumoniae DNA before
PCR [26] or with a β-actin-specific PCR on the samples
[25], however, as discussed above, testing for presence of
human DNA may not be a sufficient inhibition control.
This means that with regard to methodology, 9/11 nega-
tive studies did use sufficient DNA extraction methods or
did check for inhibitors.
When comparing PCR methods used it is seen that almost
the same number of negative and positive studies used a
nested PCR assay (5/11 negative vs. 6/13 positive studies
used nested PCR). The reason for higher positivity rates in
studies using nested PCR could be either because nested
PCRs are more sensitive or because they are more suscep-
tible to contamination, but in the selected studies (table
3) there is no clear indication of this. A large number of
positive studies used a PCR based on the PstI fragment (1/
10 negative vs. 6/13 positive studies used a PstI-fragment
based PCR). It could be speculated that either the PstI frag-
ment-based PCRs are either more prone to unspecific
amplifications or they are more sensitive. This needs to be
investigated in more detail.
Discussion of reasons for non-detection of C. pneumoniae 
in Danish samples
To date two Danish studies [6,7] and the present study
have been conducted by three different Danish research
units, and in no study has C. pneumoniae DNA been
detected in atherosclerotic tissue. Negative results were
obtained despite the use of optimised diagnostic tests and
relatively large numbers of patient samples. The frequency
of atherosclerosis in Denmark is not lower than in e.g.
USA, England and Italy, where C. pneumoniae has been
found in atherosclerotic tissue (Table 2) with high preva-
lence. These facts argue against a correlation of C. pneumo-
niae and cardiovascular disease.
Table 3: Publications with positive/negative results on direct detection by PCR of C. pneumoniae in atheroscle-rotic tissue
Authors Year PCR method DNA purification Samples collected in PCR positive (%)
Wessely et al. [20] 2003 Semi-nested, 474-bp PstI fragment phenol/chloroform Germany 0/31 (0.0)
Nested, MOMP gene
Vainio et al. [21] 2002 Nested, MOMP gene QIAmp Tissue kit Norway 0/48 (0.0)
Ong et al. [22] 2001 Nested, MOMP gene QiAmp Tissue Kit Northern Ire 0/44 (0.0)
Meijer et al. [23] 2000 Single-step, 16S rRNA and MOMP genes Easy-DNA Kit, modified The Netherlands 0/13 (0.0)
Meijer et al. [24] 1999 Single-step, 16S rRNA and MOMP genes Easy-DNA Kit, modified The Netherlands 0/18 (0.0)
Palfrey et al. [15] 1999 Single-step, MOMP gene Gene Clean Kit England 0/8 (0.0)
Lindholt et al. [6] 1998 Nested, MOMP gene phenol/chloroform Denmark 0/124 (0.0)
Andreasen et al. [7] 1998 Multiplex, Chlamydia species Chelex 100 Denmark 0/22 (0.0)
Daus et al. [25] 1998 Semi-nested, 474-bp PstI fragment Proteinase K Germany 1*/29 (3.4)
Paterson et al. [26] 1998 Nested, omp1 gene Proteinase K Australia 0/49 (0.0)
Weiss et al. [27] 1996 Single-step, 16S rRNA gene Proteinase K Brooklyn, USA 0/58 (0.0)
Cochrane et al. [28] 2002 Single-step, 474-bp PstI fragment Qiamp Tissue Kit Australia 15/29 (51.7)
Valassina et al. [29] 2001 Single-step, omp1, 16S rDNA, Hsp70 gene Qiamp Tissue Kit Italy 13/58 (58.0)
Gutierrez et al. [30] 2001 Semi-nested, 474-bp PstI fragment High Pure PCR Template 
preparation Kit
Spain 48/85 (56.5)
Farsak et al. [31] 2000 Single-step, 16S rDNA phenol/chloroform +CTAB Turkey 12/46 (26)
Jantos et al. [32] 1999 Single-step, omp1, 16S rDNA Proteinase K Germany 4/50 (8.0)
Wong et al. [33] 1999 Nested, omp1 phenol/chloroform England 26/68 (38)
Petersen et al. [34] 1998 Single-step, omp1 Qiamp Tissue Kit Sweden 14/40 (35.0)
Ouchi et al. [35] 1998 Nested, 474-bp PstI fragment phenol/chloroform Japan 16/29 (55.2)
Maass et al. [36] 1997 Nested, 474-bp PstI fragment phenol/chloroform +CTAB Germany 9/61 (14.8)
Ong et al. [37] 1996 Nested, MOMP gene phenol/chloroform England 19/43 (44.2)
Blasi et al. [38] 1996 Nested, 16S rDNA phenol/chloroform Italy 26/51 (51.0)
Campbell et al. [39] 1995 Single-step, 474-bp PstI fragment phenol/Chloro form or Qiamp USA 12/38 (31.6)
Kuo et al. [40] 1993 Single-step, 474-bp PstI fragment, 16S 
rDNA
Phenol/chloroform South Africa 12/30 (40.0)
*The single positive specimen was not positive on retestingBMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/19
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A number of circumstances could explain why C. pneumo-
niae has not been demonstrated in atherosclerotic sam-
ples from Danish patients. From other studies it seems
probable that there are great inter-laboratory differences
in the handling of both the PCR and DNA extraction
methods [8]. Several multicenter comparison trials have
also shown that some laboratories may have contamina-
tion problems [8,42]. Consequently, it could be argued
that high detection rates of C. pneumoniae DNA in athero-
sclerotic tissue, at least in part, may be caused by
contamination. A recent study has for example shown that
the nested PCR is highly unreliable for C. pneumoniae
detection because it is very prone to contamination [43].
On the other hand it could be argued that the negative
studies used insensitive or inappropriate techniques.
However, the present study and most other studies with
negative results have attempted to optimise methods to
ensure optimal sample preparation or inhibition control
and they used a sensitive PCR technique. However, as dis-
cussed above it may be necessary to optimise methods fur-
ther and to include more samples from each patient [19].
It is possible that divergence between studies is caused by
periodical presence of C. pneumoniae in blood vessels
dependent on the local epidemic conditions and C. pneu-
moniae is just transiently present during epidemics. The C.
pneumoniae seroprevalence is not as high in Denmark as in
many other countries where seroprevalence is often over
50%. Among Danish blood donors without respiratory
tract symptoms it was approximately 40% [44]. In Den-
mark there has apparently not been a C. pneumoniae epi-
demic since the early eighties [45]. One study found 1.3%
(28/ 2219 samples) prevalence of C. pneumoniae by cul-
ture and PCR in Danish respiratory tract samples sent to
the Chlamydia laboratory at Statens Serum Institut in
Denmark from 1993 to 1995. (Most routine detection of
C. pneumoniae in Denmark is performed at Statens Serum
Institut) [46]. This low prevalence of C. pneumoniae in res-
piratory tract samples may explain why C. pneumoniae
DNA is not found in the Danish atherosclerotic tissue as
the vascular C. pneumoniae infections are likely to origi-
nate from the respiratory tract infections. In table 3 it is
seen that the prevalence of C. pneumoniae in atheroscle-
rotic tissue from different countries varies between 0–
58%, which indicates variations that may be caused by
local epidemic conditions, even though not all positive
studies published are represented in the table. However,
no countries at present maintain sentinel surveillance of
C. pneumoniae infections and results from local health
authorities and research reports have not yet provided evi-
dence that different epidemic conditions could cause the
differences.
Conclusions
In conclusion we found that: 1) The DNeasy Tissue kit
and the MagNA Pure method were the methods with the
highest recoveries when five DNA extraction methods
were tested on four different sample panels. Therefore, in
our hands, these two methods are most suitable for puri-
fication of DNA from atherosclerotic tissue, when using
our LightCycler real-time PCR for C. pneumoniae DNA
quantification in the samples. 2) DNA was purified from
78 atherosclerotic tissue samples with both methods.
Danes in this study did not seem to harbor C. pneumoniae
in atherosclerotic tissue, which confirms previous Danish
studies. However, the fact that human DNA levels varied
could indicate that the likelyhood of detecting C. pneumo-
niae vary despite optimisation and test of the methods. 3)
Inhibitor levels were seemingly low in the purified DNA
from the patients samples, as C. pneumoniae DNA used for
spiking of the 2 × 78 DNA preparations from the patient
samples could be refound in them all. 4) Further testing
of DNA extraction methods is needed as this study has
shown considerable intra- and inter-method variation in
DNA recovery. Future studies could focus on using real-
time PCR for investigation of the PCR kinetics in samples
purified with different DNA extraction methods as this
might more accurately reflect the amount of PCR inhibi-
tors left in the samples.
Methods
Preparation of C. pneumoniae genomic DNA
C. pneumoniae was cultivated and EB purified as described
previously [47]. C. pneumoniae DNA was purified from EB
with the Qiagen Blood and Cell culture DNA Midi Kit as
instructed by the manufacturer and concentration was
measured with a spectrophotometer as previously
described [9,10].
Sample panels
Atherosclerotic tissue homogenates samples spiked with C. 
pneumoniae DNA
2.5 g of human aorta tissue was homogenised in TE-buffer
with a hand-held homogenisator with rotating knives.
The volume of the homogenate was increased to 25 ml
with TE-buffer and divided into 5 ml portions. Three por-
tions were spiked with purified C. pneumoniae DNA of
known concentration. The concentrations in the homoge-
nate were after spiking: 105 copies/µl, 103 copies/µl, 10
copies/µl. Copies/µl refer to genome copies per microliter.
One portion was left unspiked as a negative control. The
four 5 ml portions were divided into 100 µl aliquots so
that each aliquot corresponded to approximately 10 mg of
tissue. Spiked homogenates were frozen in aliqouts of 100
µl at -70°C and each time a DNA purification method was
tested two aliquots for each spiking concentration and the
negative control were thawed and extracted.BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/19
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Pure DNA samples
For each DNA purification method a dilution series of C.
pneumoniae DNA with concentrations 105 copies/µl, 103
copies/µl, 10 copies/µl and a negative control without C.
pneumoniae DNA was also included. Dilutions were made
in double distilled water with 20 µg/ml yeast RNA as a car-
rier nucleic acid. Pure DNA samples were frozen in aliq-
uots of 100 µl at -70°C and each time a DNA purification
method was tested two aliquots for each DNA concentra-
tion and the negative control were thawed and extracted.
Purified EB samples
For each DNA purification method a dilution series of
purified intact C. pneumoniae EB and a negative control
was tested. The EB preparation was examined by electron
microscopy and found to consist of intact EB and very
limited amounts of intermediate forms between EB and
RB. To obtain an estimate of the number of EB in the puri-
fied EB preparation a test purification was performed with
the DNeasy Tissue kit and number of output C. pneumo-
niae genomes was quantified with the C. pneumoniae real-
time PCR as described below. The concentration in the EB
preparation was estimated to be 2.4 × 107 EB/µl. Based on
the estimate of EB concentration a dilution series of the EB
was prepared so that the last dilution would yield DNA
concentrations at or below the detection limit of the C.
pneumoniae real-time PCR. Therefore EB were diluted in
PBS to 1.2 × 10-4, 1.2 × 10-5, 1.2 × 10-6, 1.2 × 10-8 of the
original EB concentration (corresponding to approximate
EB concentrations of 2000, 200, 20, 0.2 and 0 EB/µl).
Samples were frozen in aliquots of 100 µl at -70°C and
each time a DNA purification method was tested two aliq-
uots for each DNA concentration and the negative control
were thawed and extracted.
Atherosclerotic tissue homogenates samples spiked with C. 
pneumoniae EB
2.5 g of human aorta tissue was homogenised in TE-buffer
with a hand-held homogenisator with rotating knives.
The volume of the homogenate was increased to 25 ml
with TE-buffer and divided into 5 ml portions. Four por-
tions were spiked with purified C. pneumoniae EB of
known concentration and one left unspiked as a negative
control. The EB concentrations were the same as in the
purified EB samples. The five 5 ml portions were divided
into 100 µl aliquots so that each aliquot corresponded to
approximately 10 mg of tissue. Spiked homogenates were
frozen in aliqouts of 100 µl at -70°C and each time a DNA
purification method was tested two aliquots for each spik-
ing concentration and the negative control were thawed
and extracted.
DNA extraction methods
Phenol/chloroform extraction
To the 100 µl sample was added lysis-buffer (30 mM tris-
HCl pH 8.0, 30 mM EDTA, 150 mM NaCl, 0.5% SDS,
0.5% Triton X-100, 0.5% Tween 20) up to 250 µl. 125 µg
Proteinase K was added and the samples were incubated
at 55°C until the tissue was completely digested. 5 µg
RNase was added and the samples incubated 1/2 hour at
37°C. Samples were extracted with phenol/chloroform/
isoamylethanol (25:24:1), the DNA was precipitated with
96% ethanol and 3 M sodium acetate pH 5.2, washed in
70% ethanol and dried in a vacuum centrifuge. The DNA
pellet was dissolved in 100 µl Tris-EDTA pH 8.0.
Phenol/chloroform extraction with Cetyltrimethylammonium bromide 
(CTAB) precipitation
This method was performed as described above, but with
two additional steps. After the RNase treatment 42 µl 5 M
NaCl and 33 µl 10% CTAB was added to each sample and
the samples were incubated at 65°C for 10 min. Samples
were centrifuged and the supernatant was transferred to
new tubes.
DNeasy Tissue Kit (Qiagen)
Instructions from the manufacturer were followed.
Briefly, the method consists of the following steps. The
100 µl samples were lysed with Qiagen Proteinase K and
lysis buffer, loaded onto DNeasy spin columns with a sil-
ica-gel membrane (DNA-binding), washed and eluted in
100 µl elution buffer.
Easy-DNA Kit (Invitrogen)
Instructions from the manufacturer were followed.
Briefly, the 100 µl sample was lysed with solution A, pre-
cipitated with solution B, and chloroform extracted. DNA
was precipitated with ethanol and the washed and dried
pellet was resuspended in 100 µl Tris-EDTA pH 8.0.
MagNA Pure LC DNA Isolation Kit III (Roche)
Instructions from the manufacturer were followed.
Briefly, the 100 µl samples were lysed with Bacterial Lysis
Buffer and Proteinase K for 10 min. at 65°C. Samples were
then boiled for 10 min. at 95°C to inactivate microorgan-
isms and transferred to the MagNA Pure LC instrument.
This instrument handles all subsequent pipetting and
magnetic isolation. A buffer containing a chaotrophic salt
and Magnetic Glass Particles was added. DNA binds to the
Magnetic Glass Particles and they are recovered with a
magnet. Unbound molecules are removed by several
washing steps and DNA is eluted in 100 µl elution buffer.
C. pneumoniae DNA real-time PCR
The real-time PCR was performed on 2 µl of the purified
samples in a total PCR volume of 20 µl as described earlier
[9] with addition of 1.5 U heat-labile Uracil-DNABMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/19
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Glycosylase (Roche, Denmark) to ensure that amplicon
contamination was not present. Briefly, a standard dilu-
tion series of purified genomic C. pneumoniae DNA with
concentrations 105, 104, 103, 102, 10, 5, 1 copies/µl were
used for quantification, here 2 µl was also added to a total
PCR volume of 20 µl. The standard dilution series and a
reagent negative control were included in all PCR runs.
The lowest concentration (1 copy/µl) can be detected in
approximately 70% of PCR runs [9]. As 2 µl is added per
reaction it means that 2 copies of the genome per reaction
can be detected in 70% of experiments. Therefore, the
real-time PCR is highly sensitive. Primers amplified a 140
bp fragment from the pmp4 gene and it was detected with
a set of fluorescence resonance energy transfer (FRET)
probes also specific for the pmp4 gene in a Lightcycler
instrument (Roche). The pmp4 gene is a single copy gene
and it belongs to the pmp gene family, which encodes the
polymorphic membrane proteins. PCR was performed
with the enzyme mix Faststart DNA Master Hybridization
Probes (Roche) as described [9], except that incubation at
room temperature was added before starting the cycling
program to allow the Uracil-DNA Glycosylase to work.
For each unknown sample the threshold cycle was meas-
ured for two replicates, and the DNA concentrations were
calculated using the Lightcycler software, and the mean
concentration for each sample was used for analysis.
Human DNA real-time PCR
The number of human genomes in the patient samples
was determined by quantitative real-time PCR. Identical
primers can be used for both the mouse and the human
gap  genes [10]. Primers amplified a 155 bp amplicon,
which was detected with a FRET probe set. Lightcycler PCR
was performed as described earlier except that the stand-
ard dilution series was 104, 103, 102, 10, 5, 1 copies/µl of
human genomic DNA. Human genomic DNA was puri-
fied from Hep-2 cells with the Qiagen Blood and Cell cul-
ture DNA Midi Kit following descriptions from the
manufacturer and DNA concentration was determined by
measuring OD at 260 nm as previously described [9,10].
Mycoplasma mycoides PG3 DNA was used as carrier nucleic
acid at a concentration of 10 µg/ml.
Precautions to avoid contamination
To avoid contamination we took a number of precau-
tions. 1) DNA preparation, PCR preparation and PCR
were performed in physically separated rooms. 2) Filter
pipette tips were used for all pipettings. 3) PCR was per-
formed with the Faststart DNA Master Hybridisation
Probes kit, which contains dUTP instead of dTTP; this
gives the opportunity to remove amplicon contamination
with Uracil DNA Glycosylase. 4) The Lightcycler operates
with a closed-tube system, where it is not necessary to
open tubes after a PCR run, this minimises contamination
especially with amplicon. 5) If tubes were broken by acci-
dent, the contaminated equipment was immediately
decontaminated with DNAZap from Ambion. 6) In every
PCR run at least one reagent negative control was
included. 7) Extractions of C. pneumoniae DNA negative
samples were included for each DNA purification to
ensure that contamination was not introduced during
purification.
Test of the five DNA extraction methods
All DNA extraction methods were tested on 100 µl of the
four sample types; 1) pure C. pneumoniae DNA samples
with concentrations 105, 103, 10 and 0 copies/µl, 2)
atherosclerotic tissue homogenate spiked with pure C.
pneumoniae DNA so that concentrations were 105, 103, 10
and 0 copies/µl in the spiked samples. 3) Purified C. pneu-
moniae EB in dilutions 1.2 × 10-4, 1.2 × 10-5, 1.2 × 10-6, 1.2
× 10-8 and a negative control containing PBS only (corre-
sponding to approximate EB concentrations of 2000, 200,
20, 0.2 and 0 EB/µl). 4) atherosclerotic tissue homogenate
spiked with purified C. pneumoniae EB in dilutions 1.2 ×
10-4, 1.2 × 10-5, 1.2 × 10-6, 1.2 × 10-8 and a negative control
(corresponding to approximate EB concentrations of
2000, 200, 20, 0.2 and 0 EB/µl). As end point for all meth-
ods samples were dissolved or eluted in a 100 µl volume.
For each DNA purification method two replicates of each
concentration and from each sample type (i.e. 26 samples
per method) were purified. Subsequently, copies/µl of C.
pneumoniae genomic DNA were determined for 2 µl of
each sample by real-time PCR in the Lightcycler. Recovery
percentages were calculated (Table 1) for each concentra-
tion of pure DNA samples and spiked aorta samples. For
the purified EB samples output concentrations were com-
pared relatively as the exact input EB concentration was
not known.
Patient samples
Samples were obtained from Caucasian Danes admitted
to the Unit of Vascular Surgery, Skejby Sygehus, Aarhus
University Hospital, Denmark in the period 1994 to 1998.
All patients underwent arterial repair due to acute or
chronic atherosclerotic disease. During the procedure tis-
sue was freshly and immediately frozen at -70° C at which
temperature it was stored until analysis. Of the 78 sam-
ples, 25 samples were obtained from 23 women with a
median age of 68 years (range: 48 to 83 years) and 53
samples were obtained from 50 men with a median age of
65 years (42 to 85 years). The samples were obtained from
the following anatomical sites; aorta (5), carotid artery
(23), iliac artery (7), femoral artery (38), and popliteal
artery (3).
Purification of DNA from patient samples, real-time PCR 
quantification and inhibition test
DNA was purified with the DNeasy Tissue kit and the
MagNA Pure method. This kit has a maximum tissueBMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/19
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input of 25 mg. To attempt to even out differences in dif-
ferent regions of the tissue samples, approximately 100
mg of tissue from each sample was cut in small pieces with
a scalpel. An aliquot corresponding to 25 mg was subse-
quently used for purification with the DNeasy Tissue kit/
MagNA Pure method and DNA was eluted in 100 µl. C.
pneumoniae  genomic DNA concentration and human
genomic DNA concentration were determined using 2 µl
of sample with the Lightcycler real-time PCR quantitative
assays described above. For both PCR assays concentra-
tions were determined for two replicates of each of the 78
samples and average concentration was calculated. All
samples were tested for inhibition by spiking with two dif-
ferent concentrations of C. pneumoniae genomic DNA. Ten
µl clinical sample was spiked with either 10 µl of 103 cop-
ies/µl or 10 copies/µl of C. pneumoniae genomic DNA.
These relatively large spike volumes were used in order to
reduce uncertainties introduced by pipetting. For real-
time quantitative PCR was used 4 µl of the spiked sample
in a 20 µl total PCR volume. Four µl was used in the PCR
instead of 2 µl to compensate for the dilution of the sam-
ples done during the spiking process.
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